FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924904145> ?p ?o ?g. }

• W2924904145 endingPage "107" @default.
• W2924904145 startingPage "107" @default.
• W2924904145 abstract "OBJECTIVES/SPECIFIC AIMS: In the present study, we examined the functional consequences of 3α-PVA on OATP1B1-mediated PVA transport. To elucidate this, we determined the effect of SLCO1B1 genotype on PVA transport and the role of 3αPVA as a competitive inhibitor of OATP1B1, which could serve as another covariate that disrupts the systemic and hepatic exposure of pravastatin in children and adults. METHODS/STUDY POPULATION: Site directed mutagenesis was performed to generate SLCO1B1 genotypes of interest (*1a, *1b, *5, *15). Human embryonic kidney (HEK293) cells were grown and plated at 200 000 cells per well in 24-well plates. Twenty-four hours later the cells were transfected with the aforementioned plasmids. Forty-eight hours later cell-based transport was performed with radiolabelled [3H]-pravastatin sodium salt. Non-radioactive pravastatin sodium salt and 3’α-iso-pravastatin sodium salt was used for PVA transport and 3αPVA studies, respectively. Cells were washed 3 times with warm uptake buffer, incubated for 1 minute with uptake solutions containing PVA and 3αPVA at varying concentrations. Transport was terminated by four 1-ml washes with ice-cold uptake buffer. Cells were lysed with 300 µl 1% Triton X-100 in PBS at room temperature for 30 minutes prior to analysis. Radioactivity was measured in a MicroBeta2 liquid scintillation counter. The remaining cell lysates were transferred to 96-well plates to determine total protein concentration using the bicinchonic acid protein assay. All transport measurements were corrected by the total protein concentration. All experiments were performed 3 to 4 times independently with 2-3 determinations. Data were analyzed for significant differences amongst genotype groups using ANOVA followed by Tukey’s multiple comparisons test. IC50 and kinetic parameters were calculated using non-linear regression analysis. RESULTS/ANTICIPATED RESULTS: Pravastatin transport in SLCO1B1 variants (*5, *15) was significantly decreased compared to the reference genotype *1a and *1b (Km [µM]: *1a 18.2 ± 0.9; *1b 17.9 ± 3.3; *5 34.2 ± 9.7; *15 34.1 ± 6.1; p≤0.05; Vmax [pmol/mg/min]: *1a 104.9 ± 13.1; *1b 93.7 ± 16.7; *5 44.8 ± 15.9; *15 62.3 ± 22.5; p≤0.05). *1a and *1b were not significantly different with respect to pravastatin transport. Intrinsic clearance was diminished nearly 4 to 5-fold in SLCO1B1 variants compared to reference genotypes (Vmax/Km [µl/min/mg]: *1a 5.8 ± 0.8; *1b 5.7 ± 1.9; *5 1.3 ± 0.2; *15 1.8 ± 0.3; p≤0.01). Pravastatin transport was inhibited by 3αPVA for all genotypes. However, there was more pronounced inhibition in the SLCO1B1 variant genotypes compared to reference genotypes (IC50 [µM]: *1a 15.9 ± 1.9; *1b 18.6 ± 5.7; *5 3.9 ± 2.0; *15 4.4 ± 0.8; p≤0.01; Ki: *1a 15.0 ± 1.8; *1b 17.5 ± 5.4; *5 3.8 ± 2.9; *15 4.3 ± 0.8; p≤0.01). DISCUSSION/SIGNIFICANCE OF IMPACT: In vitro PVA transport is altered according to SLCO1B1 genotype, consistent with previous in vitro and human experience. Our data suggest that the significantly different maximal transport velocity (Vmax) in variant versus non-variant genotypes is consistent with decreased membrane expression of OATP1B1 with the variant c.521T>C allele. However, in contrast to data involving typical model substrates (e.g. estrone-3-sulfate), the PVA binding affinity (Km) was significantly different between variant and non-variant genotypes, consistent with altered binding of the substrate to OATP1B1. Collectively, we conclude that decreased OATP1B1 expression and function in variant genotypes influence altered transport for PVA. Finally, the functional consequences of 3αPVA formation on PVA transport was confirmed in our study. Mechanistically, we confirmed our observation in humans that 3αPVA inhibits OATP1B1 transport. However, this effect is more pronounced in variant genotypes as shown by lower IC50 values compared to the reference genotypes. This highlights another source of variation that must be taken into consideration when trying to optimize the pravastatin dose-exposure relationship in humans." @default.
• W2924904145 created "2019-04-01" @default.
• W2924904145 creator A5005624600 @default.
• W2924904145 creator A5009370933 @default.
• W2924904145 creator A5063675300 @default.
• W2924904145 creator A5073680043 @default.
• W2924904145 date "2019-03-01" @default.
• W2924904145 modified "2023-09-26" @default.
• W2924904145 title "3012 Functional consequences of pravastatin isomerization on OATP1B1-mediated transport" @default.
• W2924904145 doi "https://doi.org/10.1017/cts.2019.243" @default.
• W2924904145 hasPublicationYear "2019" @default.
• W2924904145 type Work @default.
• W2924904145 sameAs 2924904145 @default.
• W2924904145 citedByCount "0" @default.
• W2924904145 crossrefType "journal-article" @default.
• W2924904145 hasAuthorship W2924904145A5005624600 @default.
• W2924904145 hasAuthorship W2924904145A5009370933 @default.
• W2924904145 hasAuthorship W2924904145A5063675300 @default.
• W2924904145 hasAuthorship W2924904145A5073680043 @default.
• W2924904145 hasBestOaLocation W29249041451 @default.
• W2924904145 hasConcept C1491633281 @default.
• W2924904145 hasConcept C153911025 @default.
• W2924904145 hasConcept C178790620 @default.
• W2924904145 hasConcept C185592680 @default.
• W2924904145 hasConcept C2778163477 @default.
• W2924904145 hasConcept C2779519902 @default.
• W2924904145 hasConcept C2908647359 @default.
• W2924904145 hasConcept C43617362 @default.
• W2924904145 hasConcept C537181965 @default.
• W2924904145 hasConcept C55493867 @default.
• W2924904145 hasConcept C57409179 @default.
• W2924904145 hasConcept C71924100 @default.
• W2924904145 hasConcept C86803240 @default.
• W2924904145 hasConcept C99454951 @default.
• W2924904145 hasConceptScore W2924904145C1491633281 @default.
• W2924904145 hasConceptScore W2924904145C153911025 @default.
• W2924904145 hasConceptScore W2924904145C178790620 @default.
• W2924904145 hasConceptScore W2924904145C185592680 @default.
• W2924904145 hasConceptScore W2924904145C2778163477 @default.
• W2924904145 hasConceptScore W2924904145C2779519902 @default.
• W2924904145 hasConceptScore W2924904145C2908647359 @default.
• W2924904145 hasConceptScore W2924904145C43617362 @default.
• W2924904145 hasConceptScore W2924904145C537181965 @default.
• W2924904145 hasConceptScore W2924904145C55493867 @default.
• W2924904145 hasConceptScore W2924904145C57409179 @default.
• W2924904145 hasConceptScore W2924904145C71924100 @default.
• W2924904145 hasConceptScore W2924904145C86803240 @default.
• W2924904145 hasConceptScore W2924904145C99454951 @default.
• W2924904145 hasIssue "s1" @default.
• W2924904145 hasLocation W29249041451 @default.
• W2924904145 hasLocation W29249041452 @default.
• W2924904145 hasLocation W29249041453 @default.
• W2924904145 hasOpenAccess W2924904145 @default.
• W2924904145 hasPrimaryLocation W29249041451 @default.
• W2924904145 hasRelatedWork W1551485561 @default.
• W2924904145 hasRelatedWork W1995503186 @default.
• W2924904145 hasRelatedWork W2043142128 @default.
• W2924904145 hasRelatedWork W2050881906 @default.
• W2924904145 hasRelatedWork W2051351267 @default.
• W2924904145 hasRelatedWork W2067571365 @default.
• W2924904145 hasRelatedWork W2366104472 @default.
• W2924904145 hasRelatedWork W2402967970 @default.
• W2924904145 hasRelatedWork W2475758815 @default.
• W2924904145 hasRelatedWork W2950776738 @default.
• W2924904145 hasVolume "3" @default.
• W2924904145 isParatext "false" @default.
• W2924904145 isRetracted "false" @default.
• W2924904145 magId "2924904145" @default.
• W2924904145 workType "article" @default.